Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9057 for fluid retention due to heart failure (Phase II, China)
CTR20254666Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-9057 in heart failure (HF) (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Absolute change in body weight from baseline to Day 8. Started Dec 2025; status: active.
02
Drugs
HRS-9057
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on CTR20254666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254666.